LONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a ...
Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over one-year After 4 initiating doses in the first 6 ...
Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova (laruparetigene zovaparvovec) as a potential treatment for X-linked retinitis ...
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...
Beam Therapeutics recently reported additional safety and efficacy data from its BEACON Phase 1/2 trial of ristoglogene autogetemcel (risto-cel) for sickle cell disease, highlighting efficient ex vivo ...
WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterally LONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited ('Beacon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback